Last reviewed · How we verify

Acerus Pharmaceuticals Corporation — Portfolio Competitive Intelligence Brief

Acerus Pharmaceuticals Corporation pipeline: 1 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NATESTO Testosterone Nasal Gel NATESTO Testosterone Nasal Gel marketed Androgen replacement therapy Androgen receptor Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abbott · 1 shared drug class
  2. Acrux DDS Pty Ltd · 1 shared drug class
  3. Alliance for Clinical Trials in Oncology · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Beersheva Mental Health Center · 1 shared drug class
  6. Clarus Therapeutics, Inc. · 1 shared drug class
  7. Imperial College Healthcare NHS Trust · 1 shared drug class
  8. Laboratoires Besins International · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Acerus Pharmaceuticals Corporation:

Cite this brief

Drug Landscape (2026). Acerus Pharmaceuticals Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acerus-pharmaceuticals-corporation. Accessed 2026-05-17.

Related